Univariate sensitivity analysis.
| Variables | Sensitivity Analysis, Range | ICER, Range | |
|---|---|---|---|
| Annual | Biannual | ||
| HRQOL weights | |||
| 0 | 0.695–0.765 | 7546–17,813 | 9469–22,350 |
| 1 | 0.685–0.755 | 7737–13,678 | 9708–17,162 |
| 2 | 0.685–0.755 | 9118–16,678 | 11,441–17,162 |
| 3 | 0.633–0.707 | 9947–25,449 | 12,481–31,928 |
| 4 | 0.602–0.678 | 12,809–16,437 | 16,071–20,624 |
| Probabilities of gout flares/yr | |||
| Nonadherent to therapy | |||
| 0 | 0.33–0.42 | 9283–17,541 | 12,428–21,324 |
| 1 | 0.2–0.3 | 13,184–14,137 | 16,619–17,666 |
| 2 | 0.22–0.32 | 11,312–16,223 | 14,841–19,659 |
| 3 | 0.06–0.12 | 8334–23,383 | 11,116–28,141 |
| 4 | 0–0.04 | 6199–17,933 | 8673–21,991 |
| Adherent to therapy | |||
| 0 | 0.46–0.56 | 11,112–16,830 | 14,430–20,519 |
| 1 | 0.23–0.33 | 12,339–14,981 | 15,694–18,591 |
| 2 | 0.14–0.24 | 9371–17,871 | 12,726–21,481 |
| 3 | 0–0.07 | 9149–24,446 | 12,059–29,294 |
| 4 | 0–0.04 | 13,678–34,258 | 17,162–40,451 |
| Effectiveness of urate monitoring in improving adherence, % | ≥ 40 (equivalent to no monitoring) | Annual monitoring cost effective at adherence rate > 41.6 | Biannual monitoring cost effective > adherence rate of 43.4 |
| Rates of flare treatment, % | |||
| Hospital | 1–12 | 13,678–30,728 | 14,162–34,212 |
| Home | 0–20 | 11,024 to dominant | 14,508 to dominant |
| Patients taking febuxostat vs allopurinol, % | 0–10 | 13,461–24,295 | 16,945–27,778 |
ICER: incremental cost-effectiveness ratio; HRQOL: health-related quality of life.